创新药海外授权持续落地，创新药ETF（517110）涨近1.5%，短期回调或迎来布局良机

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a rebound due to continuous overseas licensing and clinical data releases, with the innovative drug ETF (517110) rising nearly 1.5% [1] - Xiangcai Securities indicates that after ten years of sustained investment in innovative drugs, the sector is entering a phase of results realization, supported by continuous clinical data releases and accelerated commercialization [1] - The medical and biological industry is significantly influenced by policy support and innovation, with the National Medical Products Administration recently approving measures to support high-end medical device innovation [1] Group 2 - The innovative drug ETF, Guotai (517110), tracks the SHS Innovative Drug (RMB) Index (931409), which includes listed companies involved in the research, production, and sales of innovative drugs [2] - The index reflects the overall performance of listed companies in the innovative drug sector, focusing on the biopharmaceutical industry [2] - The overall valuation of the industry is at a historical low (PE 27.22 times), with innovative drugs, high-end devices, and the CXO industry chain remaining core investment themes [1]